Fish, Fish-Derived n-3 Fatty Acids, and Risk of Incident Atrial Fibrillation in the Atherosclerosis Risk in Communities (ARIC) Study

Noelle N. Gronroos1, Alanna M. Chamberlain2, Aaron R. Folsom1, Elsayed Z. Soliman3, Sunil K. Agarwal4, Jennifer A. Nettleton5, Alvaro Alonso1*

1 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America, 2 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 3 Epidemiological Cardiology Research Center (EPICARE), Wake Forest University School of Medicine, Winston Salem, North Carolina, United States of America, 4 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5 Division of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

Abstract

Background: Results of observational and experimental studies investigating the association between intake of long-chain n-3 polyunsaturated fatty acids (PUFAs) and risk of atrial fibrillation (AF) have been inconsistent.

Methods: We studied the association of fish and the fish-derived n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with the risk of incident AF in individuals aged 45–64 from the Atherosclerosis Risk in Communities (ARIC) cohort (n = 14,222, 27% African Americans). Intake of fish and of DHA and EPA were measured via food frequency questionnaire. Plasma levels of DHA and EPA were measured in phospholipids in a subset of participants (n = 3,757). Incident AF was identified through the end of 2008 using ECGs, hospital discharge codes and death certificates. Cox proportional hazards regression was used to estimate hazard ratios of AF by quartiles of n-3 PUFAs or by fish intake.

Results: During the average follow-up of 17.6 years, 1,604 AF events were identified. In multivariable analyses, total fish intake and dietary DHA and EPA were not associated with AF risk. Higher intake of oily fish and canned tuna was associated with a nonsignificant lower risk of AF (p for trend = 0.09). Phospholipid levels of DHA+EPA were not related to incident AF. However, DHA and EPA showed differential associations with AF risk when analyzed separately, with lower risk of AF in those with higher levels of DHA but no association between EPA levels and AF risk.

Conclusions: In this racially diverse sample, dietary intake of fish and fish-derived n-3 fatty acids, as well as plasma biomarkers of fish intake, were not associated with AF risk.

Introduction

Consumption of fish and fish-derived n-3 PUFAs has been shown to reduce the risk of cardiovascular disease [1,2], particularly sudden cardiac death [3]. Similarly, consumption of fish and n-3 PUFAs has been associated with more favorable heart rate variability indices [4], and reduced risk of ventricular arrhythmias [5] and all-cause mortality post myocardial infarction (MI) [6].

Intake of fish and the fish-derived n-3 fatty acids DHA and EPA may also reduce the risk of atrial fibrillation (AF), a common cardiac arrhythmia associated with increased stroke and cardiovascular morbidity and mortality, which affects more than 2 million Americans [7]. However, studies investigating the association between fish-derived n-3 PUFAs and incident AF have had inconsistent results [8,9,10,11,12,13,14,15,16].

These observed inconsistencies may be due, in part, to differences in dietary assessment methods, absolute quantities of fish consumed, and dietary patterns associated with fish consumption across different study populations. Specifically, measurement error of fish intake, or any other dietary exposure, poses a concerning issue since self-reported information is subject to recall bias and biomarkers of fish intake (such as plasma levels of DHA and EPA) only reflect exposure over a limited period of time and are affected by multitude of metabolic processes [17]. Using a combination of self-reported and objective measures (biomarkers) of fish consumption in the same population might provide a more accurate representation of the association with AF risk taking...
advantage of the strengths of each method. Therefore, we used both self-reported measures of fish and dietary EPA and DHA intake (derived from food frequency questionnaires (FFQ)) and phospholipid measures of EPA and DHA to test the hypothesis that fish and EPA and DHA are inversely associated with the risk of incident AF in the Atherosclerosis Risk in Communities (ARIC) Study, a population based cohort of middle aged American men and women.

Methods

Study Population

The ARIC study has been described previously [18]. Briefly, ARIC is a prospective study of cardiovascular disease including 15,792 men and women aged 45–64 years of age at baseline from four US communities: Forsyth County, NC; Jackson, MS; Minneapolis suburbs, MN; and Washington County, MD. Baseline data were collected in 1987–89. Three additional exams were done at 3-year intervals (1990–92, 1993–95, 1996–98). Follow-up for cardiovascular outcomes is available through 2008. The ARIC study has been approved by the Institutional Review Boards (IRB) of all participating institutions, including the IRBs of the University of Minnesota, Johns Hopkins University, University of North Carolina, University of Mississippi Medical Center, and Wake Forest University. All participants gave written informed consent in each one of the study visits.

AF ascertainment

Incident cases of atrial fibrillation through December 31, 2008 were identified from three sources: hospital discharge codes (International Classification of Diseases, Ninth Revision (ICD-9) codes 427.31 and 427.32), electrocardiograms (ECGs) performed during follow-up exams, and death certificates (ICD-9 code 437.3 or ICD-10 code 146) [19]. The positive predictive value of hospital discharge codes for the diagnosis of incident AF, as determined after review of hospital discharge summaries in a sample of ARIC participants, was 89% [20].

Exposure assessment

Dietary intake of fish and the fish-derived PUFAs DHA and EPA was ascertained using both self-report and biomarkers. Participants reported their usual intake of different types of fish via a food frequency questionnaire (FFQ). Additionally, blood plasma levels of DHA and EPA were measured in a subset of participants.

Fish intake via FFQ: Participants’ usual dietary intake of fish was assessed by an interviewer-administered, 66-item FFQ. The FFQ was a slightly modified version of the instrument developed by Willett et al [21]. The FFQ was administered to all subjects at baseline (1987–1989) and Exam 3 (1993–1995). For each food, participants were asked to report the frequency of consumption over the past year in 9 categories, ranging from “never or less than once per month” to “>6 times per day.” Interviewers used food models to help with portion size estimation. Fish and other seafood intake was assessed through 4 questionnaire items: (1) 3–4 ounces of canned tuna fish; (2) 3–5 ounces of dark meat fish such as salmon, mackerel, swordfish, sardines, and bluefish; (3) 3–5 ounces of other fish such as cod, perch, catfish, etc.; and (4) shrimp, lobster, scallops as a main dish. FFQ responses were translated into servings per week and subsequently categorized into four categories: none, less than 1, 1–2, and more than two. The FFQ did not collect information on fish preparation method.

DHA and EPA via FFQ: Nutrient values for each food were obtained from the Harvard database [21] and daily intake of nutrients was calculated by multiplying the nutrient content of each food in the portion specified by the frequency of daily consumption and then summing the results. This calculation yielded consumption of EPA and DHA in grams/day. Fish-derived n-3 fatty acid intake in visits 1 and 3 were significantly correlated (r = 0.47, p<0.0001, adjusted for age, race, and sex).

DHA and EPA in Plasma: Fatty acids levels were measured in plasma samples from the Minnesota field center participants (n=3,757) at baseline. Fatty acids were measured in plasma cholesterol esters and phospholipids using gas chromatography, yielding measures of plasma DHA and EPA as a percentage of total fatty acids. The fatty acid profile of cholesterol esters reflects medium-term (weeks) dietary intake of fatty acids while phospholipids reflect intake over a slightly longer duration (weeks to months) [22]. Only phospholipid measurements were used for the present analysis.

Previous analyses in ARIC have shown that plasma DHA and EPA measures correlate with dietary intake (as measured via a food frequency questionnaire) with correlation coefficients ranging from 0.20 (EPA) to 0.42 (DHA) [23].

Assessment of other variables: Cigarette smoking status and amount, exercise amount, systolic blood pressure, LDL and HDL cholesterol, alcohol intake, antihypertensive medication use, diabetes status, anti-hyperglycemic medication use, weight, height, and educational status were measured at baseline using standardized methods [18]. Diabetes was defined as fasting blood glucose ≥126 mg/dl, use of anti-hyperglycemic medications, or self-reported history of physician-diagnosed diabetes. ECG-diagnosed left ventricular hypertrophy (LVH) was considered present if the Cornell voltage was >28 mm in men or >22 mm in women [24]. History of coronary heart disease (CHD) at baseline was defined as one of the following: a self-reported history of a physician-diagnosed myocardial infarction; evidence of previous myocardial infarction in the baseline ECG; history of previous heart or arterial surgery, including angioplasty or coronary bypass.

Participants with prevalent AF at baseline, who reported a race other than white or black, and those with implausible calorie intakes (<700 or >4500 for men, <500 or >3500 for women) were excluded. Participants with missing values for diabetes, prevalent CHD, or LVH at baseline were imputed as having “no disease.” Participants missing exposure values or other covariates were excluded from analysis.

Statistical analysis

Cox proportional hazards regression models were used to estimate hazard ratios (HRs) of incident AF by level of fish consumption (0, <1, 1–2, 2+ servings/week), quartiles of DHA+EPA intake, and quartiles of phospholipid DHA+EPA. Exposure status was a time-dependent covariate with baseline (visit 1) dietary data used as the exposure for the period between baseline and visit 3, and the average intake of visits 1 and 3 afterwards. If visit 3 data were not available then visit 1 data were used over the entire follow-up. The multivariable-adjusted models included the following potential confounders as measured at baseline: center, age, sex, race, BMI, total calories, alcohol intake (grams/day), saturated fat intake (grams/day), fiber intake (grams/day), vitamin C intake (mg/day), education level (less than high school, high school, more than high school), cigarette smoking status (current, former, never) and amount (pack years), LDL cholesterol, HDL cholesterol, systolic blood pressure, use of hypertensive medications, diabetes, LVH, and prevalent CHD. Tests of linear trend were conducted by assigning the median values for each category of exposure variable and modeling as a continuous variable. To assess potential U-shaped associations, tests of quadratic trend were done by using the linear trend values.
and adding a quadratic term. To determine whether method of AF ascertainment affected our results, we repeated all analyses including only AF events identified in study ECGs. We used the residual method to adjust for total energy intake in analyses considering dietary EPA and DHA as the main exposure [25].

Additional analyses were conducted combining the dietary data with the biomarker data. Multivariable Cox proportional hazard models were run using three different exposures: (1) subjects in the highest tertiles of both FFQ-derived residual-adjusted intake and phospholipid measures of DHA+ EPA vs. those in lowest tertiles vs. all others (3-level categorical variable); (2) Howe’s method [26] with three categories (tertiles); and (3) Howe’s method with n categories (n = 3,743). Howe’s method ranks individuals by categories of self-reported diet intake (DHA+EPA), then again by biomarkers (DHA+EPA), then sums the two ranks [26]. Thus, Howe’s method for three categories has a range of a combined rank from 2 (lowest tertile for both dietary and phospholipid exposures) to 6 (highest tertile for both dietary and phospholipid exposures). Howe’s method for n categories ranks all subjects in sequential order from lowest intake of DHA+EPA to highest.

Tests of the proportional hazards assumption were evaluated using a time*exposure interaction term. Sex by exposure and race by exposure interactions were also tested using a sex*exposure and race*exposure interaction term. All p-values were 2-tailed. Data were analyzed with SAS 9.2 for Windows (SAS Corp, Cary, NC).

Results

Baseline characteristics of the 14,222 eligible participants by categories of fish intake (all ARIC field centers), and the 3,757 eligible participants by quartiles of DHA+EPA phospholipid levels (Minnesota field center only) are shown in Table 1. Those who consumed more fish tended to be older, female, and have a more adverse cardiovascular risk profile. During the average follow-up time of 17.6 years (249,775 person-years), 1,604 AF events were identified. The proportional hazards assumption was not violated.

Risk of AF by Fish Intake Categories

Overall, fish intake was not associated with the incidence of AF (table 2). The multivariable HR (95% CI) of AF in those consuming >2 servings of fish/week was 1.00 (0.81–1.24) compared to those not eating any fish (p for trend = 0.15). Further categorization of individuals with >2 servings of fish/week into >2–3, >3–4, >4–5, and >5 servings/week did not show evidence of an association (data not shown). Results were similar for canned tuna (HR 0.85, 95% CI: 0.68–1.06), oily fish (HR 0.83, 95% CI: 0.58–1.21), other fish (HR 0.98, 95% CI: 0.76–1.27), and shellfish (HR 0.81, 95% CI: 0.38–1.71), comparing >2 servings/week vs. no intake. An analysis combining canned tuna and oily fish showed a non-significant lower AF risk in those with >2 servings/week vs no intake (HR 0.86, 95% CI 0.72–1.03, p for trend = 0.09). Results did not materially change when we included only AF cases identified from study ECGs.

Risk of AF by DHA and EPA Intake

Intake of DHA+EPA was not associated with the incidence of AF, with a HR (95% CI) of 0.92 (0.79–1.07) comparing extreme quartiles (Table 3). Similar results were found when dietary DHA and EPA were analyzed separately.

Risk of AF by Phospholipid Levels of DHA and EPA

Among the 3,757 eligible ARIC participants from the Minneapolis center with measurements of phospholipid fatty acids, 401 AF events occurred during an average follow-up time of 17.9 years (67,081 person-years).

In multivariable analyses, the test for linear trend across quartiles of phospholipid DHA+EPA for incident AF was not statistically significant (table 4). When analyzed separately, DHA showed a marginal U-shaped association (p for quadratic term = 0.10) with highest risk in the first quartile and in the last quartile, lowest in the middle quartiles, and with point estimates below 1.00 for intakes greater than the first quartile (table 4). In contrast, EPA showed no association with the incidence of AF (Q4 vs. Q1; HR = 1.12, 95% CI: 0.83–1.49).

Risk of AF by Combined Dietary and Biomarker Categories

Among the 3,743 ARIC participants from the Minneapolis center with measurements of phospholipid fatty acids and dietary fatty acid intake, 400 AF events occurred during an average follow-up of 17.9 years (66,834 person-years).

Participants with both dietary intake and phospholipid levels of DHA+EPA in the highest tertiles did not have significantly different risk of AF compared with those in the lowest tertiles (table 5). Howe’s method with three categories yielded similar results as well (table 5). Finally, Howe’s method with n categories (n = 3,743) did not provide any evidence of an association between n-3 PUFA intake and AF risk. Comparing the estimated hazard ratio for the subject with the lowest intake of DHA+EPA (rank = 1) with the highest (rank = 3,743) yielded a hazard ratio of 0.92 (95% CI: 0.74–1.14). Results were similar when exposure was restricted to intake of oily fish and canned tuna, and biomarker data on DHA (data not shown).

Discussion

In this population-based study of middle-aged adults, we did not observe strong associations of fish intake or dietary EPA and DHA with risk of AF. However, our results suggest that the association between fish-derived phospholipid n-3 PUFAs may differ for individual fatty acids.

Overall, our results are consistent with those from the Women’s Health Initiative [8], the Rotterdam Study [9], the Framingham Heart Study [13], and the Danish Diet, Cancer, and Health Study [10]: four large prospective cohorts that also failed to observe an association between fish intake and AF risk. Only one previous analysis in the Cardiovascular Health Study, involving a cohort of Americans aged 65 years and older, found that higher consumption of tuna or other non-fried fish was associated with a 30% lower risk of AF (5+ servings/week vs. <1 serving/month, RR = 0.70, 95% CI: 0.53–0.93) [12]. Notably, the Cardiovascular Health Study had a large proportion of subjects with high fish consumption (19% ate 5+ servings/week of tuna or other fish vs. 8.3% in ARIC), suggesting that a higher intake than that observed in the present study might be necessary to illicit any effect on AF risk as has been observed for other cardiovascular outcomes [12,27]. Our finding that higher intake of oily fish and canned tuna in the ARIC cohort was associated with a lower, though non-significant, risk of AF is consistent with the results from the Cardiovascular Health Study.

Our data suggested that phospholipid EPA and DHA may be differentially associated with AF risk, with no association between EPA levels and AF risk and a U- or L-shaped association between DHA and AF risk. Two previous studies have explored the associations between blood levels of DHA and EPA—as biomarkers of fish intake—and AF risk. A Finnish prospective study found an inverse association between blood serum levels of total fish-
derived n-3 PUFAs (RR = 0.50, 95% CI: 0.31–0.80, comparing extreme quartiles) and DHA (RR = 0.51, 95% CI: 0.32–0.82, comparing extreme quartiles) with incident AF, but no association was seen for other n-3 PUFAs (EPA, docosapentaenoic acid) [14]. Very similar results were found in the Cardiovascular Health Study [16]. ARIC results are somewhat consistent with these two studies, though fish intake in both studies was higher than that observed in the ARIC cohort. In ARIC subjects, the highest DHA + EPA quartile contained values of 3.83% whereas Finland’s Kuopio Ischemic Heart Disease Risk Factor Study had values of 3.61% in the lowest quartile and 3.53% in the highest [14], and average total n-3 PUFA concentration in the Cardiovascular Health Study was 4.5%. In addition, a recent small case-control study in Italy found that levels of n-3 PUFA in erythrocyte membranes were higher in cases of idiopathic AF than in controls (31.4% vs. 23.5%, p<0.001) [15], but this later study did not adjust for potential confounders and, therefore, its interpretation is problematic.

Measurement error may be partly responsible for the inconsistent results across studies. Phospholipid measurement of n-3 fatty acids, less subject to self-report measurement error, could better elucidate the relationship between n-3 fatty acids and AF. However, our results combining phospholipid and dietary data were similarly null.

Other reasons for why certain subgroups show an inverse association between n-3 PUFAs and AF include dose and relevant exposure period. Some trials [28,29,30] (but not all [31,32]) have shown that fish oil supplementation pre- and post-coronary artery bypass graft (CABG) or open heart surgery reduces the risk of AF—especially in the immediate aftermath [29]. These studies

Table 1. Baseline characteristics of ARIC participants (n = 14,222), 1987–1989.

| Serving of fish/week | 0          | <1         | 1–2        | >2         |
|----------------------|------------|------------|------------|------------|
| Number of Subjects (%) | 612 (4.3)  | 2641 (18.6) | 5686 (40)  | 5283 (37.1) |
| Age                  | 55 (6.0)   | 54.2 (5.8)  | 54.2 (5.7)  | 54 (5.7)   |
| Sex (men)            | 48.0       | 51.7       | 54.5       | 58.9       |
| Race (White)         | 88.9       | 89.6       | 76.8       | 64.5       |
| BMI                  | 27.2 (5.4) | 27.1 (4.8)  | 27.5 (5.3)  | 28.2 (5.5) |
| Hypertension         | 28.6       | 28.9       | 34.2       | 37.2       |
| Current smoking      | 29.7       | 25.2       | 26.7       | 24.5       |
| Diabetes             | 10.8       | 9.4        | 11.2       | 12.9       |
| ECG defined LVH      | 1.5        | 1.8        | 2          | 2.3        |
| CHD                  | 5.4        | 3.9        | 4.6        | 5.2        |
| Alcohol intake (g/day) | 5.6 (14.1) | 6.2 (13.8) | 6.4 (13.6) | 5.8 (13.3) |
| Total energy intake (Kcal/day) | 1504.4 (605.9) | 1478.9 (572.4) | 1561.8 (564.2) | 1747.3 (611.0) |
| Fish-derived n-3 fatty acids (g/day) | 0.02 (0.02) | 0.08 (0.05) | 0.19 (0.09) | 0.48 (0.34) |
| Fiber (g/day)        | 15.6 (8.7) | 14.9 (7.2)  | 16.4 (7.3)  | 19.7 (9)   |
| Vitamin C (mg/day)   | 104.5 (79.9) | 99.6 (73.9) | 116.4 (77.7) | 142.8 (91.6) |
| Saturated Fat (g/day) | 21.8 (11)   | 21.3 (10.5) | 21.9 (10.5) | 22.4 (10.8) |

Quartile of DHA+ EPA (Minnesota participants only, n = 3,817)

|          | Q1       | Q2       | Q3       | Q4       |
|----------|----------|----------|----------|----------|
| Range (% total fatty acid) | 0.73–2.7 | 2.71–3.2 | 3.21–3.82 | 3.83–12.19 |
| Number of Subjects (%) | 410 (21) | 483 (24.7) | 550 (28.1) | 511 (26.2) |
| Age      | 53.5 (5.6) | 53.9 (5.7) | 53.9 (5.6) | 54.4 (5.6) |
| Sex (men) | 55.68     | 48.51    | 41.8     | 46.15     |
| BMI      | 26.6 (4.4) | 27.5 (4.9) | 27.3 (4.7) | 26.7 (4.3) |
| Hypertension | 24.86     | 24.31    | 27.09    | 25.29     |
| Current smoking | 34.38     | 21.86    | 18.84    | 14.12     |
| Diabetes | 6.16      | 8        | 7.3      | 7.38      |
| ECG defined LVH | 1.19      | 0.96     | 0.74     | 0.95      |
| CHD      | 3.89      | 4.05     | 4.76     | 4.95      |
| Alcohol intake (g/day) | 9.8 (15.7) | 8.7 (14.7) | 7.6 (14.7) | 7.4 (12) |
| Fiber (g/day) | 15.5 (7.4) | 15.8 (7.3) | 16.1 (7.1) | 17.4 (7.4) |
| Vitamin C (mg/day) | 103.7 (72.2) | 109.5 (71.4) | 109.6 (62) | 119.4 (68.9) |
| Saturated Fat (g/day) | 24.9 (11.2) | 23.8 (11.3) | 22.1 (9.7) | 20.7 (9.8) |

Values are % for categorical variables and mean (SD) for continuous variables. BMI: Body mass index. CHD: Coronary heart disease. DHA: Docosahexaenoic acid. ECG: Electrocardiogram. EPA: Eicosapentaenoic acid.
used n-3 PUFA doses that exceed typical dietary intake, and were done in subjects at high risk for AF. Similarly, trials investigating n-3 PUFA supplementation once AF has been established have also shown mixed results [33,34]. This may suggest that the administration of high-dose n-3 PUFA supplementation (as opposed to usual intake) in high-risk subjects might have a preventive effect, though further research is required.

In spite of the lack of strong and consistent epidemiologic evidence for an inverse association of n-3 PUFAs with AF, several mechanisms suggest that such an effect might exist. First, fish-derived n-3 PUFAs may prevent AF by preventing the structural heart damage that is a precursor to AF. Previous research has shown that fish-derived n-3 PUFAs protect against CHD [1,2], a risk factor for AF [35]. Second, n-3 PUFAs may inhibit the inflammatory triggers that occasionally initiate the ectopic activity in AF [36,37]. Finally, even once that electrical activity has been stimulated, fish-derived n-3 PUFAs may inhibit the fast, voltage-dependent sodium current and the L-type calcium currents [38,39] that would allow the arrhythmia to be sustained.

Table 2. Hazard ratios (95% confidence intervals) of atrial fibrillation by fish intake categories, ARIC, 1987–2008.

| Total Fish (servings/week) | 0 | <1 | 1–2 | >2 | P for trend |
|---------------------------|---|----|-----|----|-----------|
| AF cases                  | 66 | 309 | 679 | 550 |           |
| Person-years              | 10,108 | 47,073 | 98,733 | 93,861 |           |
| Model 1 [HR (95% CI)]    | 1 (ref.) | 1.04 (0.84, 1.29) | 1.12 (0.92, 1.35) | 0.99 (0.80, 1.21) | 0.37 |
| Model 2 [HR (95% CI)]    | 1 (ref.) | 1.13 (0.91, 1.40) | 1.16 (0.95, 1.40) | 1.00 (0.81, 1.24) | 0.15 |

| Canned Tuna (servings/week) | 0 | <1 | 1–2 | >2 |
|-----------------------------|---|----|-----|----|
| AF cases                    | 394 | 792 | 326 | 92 |
| Person-years                | 53,825 | 125,261 | 52,237 | 18,453 |
| Model 1 [HR (95% CI)]      | 1 (ref.) | 0.97 (0.86, 1.10) | 1.01 (0.87, 1.17) | 0.94 (0.76, 1.17) | 0.77 |
| Model 2 [HR (95% CI)]      | 1 (ref.) | 0.98 (0.87, 1.11) | 0.97 (0.84, 1.13) | 0.85 (0.68, 1.06) | 0.17 |

| Oily Fish (servings/week)  | 0 | <1 | 1–2 | >2 |
|---------------------------|---|----|-----|----|
| AF cases                  | 664 | 768 | 148 | 24 |
| Person-years              | 108,509 | 114,245 | 22,226 | 4,795 |
| Model 1 [HR (95% CI)]    | 1 (ref.) | 1.04 (0.93, 1.15) | 0.99 (0.83, 1.18) | 0.89 (0.61, 1.28) | 0.67 |
| Model 2 [HR (95% CI)]    | 1 (ref.) | 1.03 (0.92, 1.14) | 0.97 (0.81, 1.16) | 0.83 (0.58, 1.21) | 0.44 |

| Canned Tuna + Oily Fish (servings/week) | 0 | <1 | 1–2 | >2 |
|-----------------------------------------|---|----|-----|----|
| AF cases                                | 425 | 429 | 572 | 178 |
| Person-years                            | 60,541 | 66,681 | 89,598 | 32,955 |
| Model 1 [HR (95% CI)]                  | 1 (ref.) | 0.96 (0.84–1.09) | 0.97 (0.85–1.10) | 0.90 (0.76–1.07) | 0.27 |
| Model 2 [HR (95% CI)]                  | 1 (ref.) | 0.98 (0.85–1.12) | 0.95 (0.83–1.08) | 0.86 (0.72–1.03) | 0.09 |

| Other Fish (servings/week)             | 0 | <1 | 1–2 | >2 |
|----------------------------------------|---|----|-----|----|
| AF cases                                | 377 | 842 | 321 | 64 |
| Person-years                            | 56,467 | 128,878 | 52,975 | 11,456 |
| Model 1 [HR (95% CI)]                  | 1 (ref.) | 1.03 (0.91, 1.17) | 0.96 (0.82, 1.12) | 0.97 (0.76, 1.26) | 0.66 |
| Model 2 [HR (95% CI)]                  | 1 (ref.) | 1.08 (0.96, 1.23) | 0.98 (0.84, 1.14) | 0.98 (0.76, 1.27) | 0.68 |

| Shellfish (servings/week)              | 0 | <1 | 1–2 | >2 |
|----------------------------------------|---|----|-----|----|
| AF cases                                | 846 | 673 | 77 | 8 |
| Person-years                            | 129,037 | 107,438 | 11,716 | 1,584 |
| Model 1 [HR (95% CI)]                  | 1 (ref.) | 1.01 (0.91, 1.12) | 1.19 (0.96, 1.49) | 0.87 (0.41, 1.83) | 0.51 |
| Model 2 [HR (95% CI)]                  | 1 (ref.) | 1.04 (0.93, 1.15) | 1.16 (0.92, 1.46) | 0.81 (0.38, 1.71) | 0.54 |

CI: Confidence interval. HR: Hazard ratio. Model 1: adjusted for age, sex, and race; Model 2: adjusted for center, age, race, sex, energy intake, body mass index, education, exercise levels, smoking status and amount, alcohol intake, LDL cholesterol, HDL cholesterol, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.

doi:10.1371/journal.pone.0036686.t002

used n-3 PUFA doses that exceed typical dietary intake, and were done in subjects at high risk for AF. Similarly, trials investigating n-3 PUFA supplementation once AF has been established have also shown mixed results [33,34]. This may suggest that the administration of high-dose n-3 PUFA supplementation (as opposed to usual intake) in high-risk subjects might have a preventive effect, though further research is required.

In spite of the lack of strong and consistent epidemiologic evidence for an inverse association of n-3 PUFAs with AF, several mechanisms suggest that such an effect might exist. First, fish-derived n-3 PUFAs may prevent AF by preventing the structural heart damage that is a precursor to AF. Previous research has shown that fish-derived n-3 PUFAs protect against CHD [1,2], a risk factor for AF [35]. Second, n-3 PUFAs may inhibit the inflammatory triggers that occasionally initiate the ectopic activity in AF [36,37]. Finally, even once that electrical activity has been stimulated, fish-derived n-3 PUFAs may inhibit the fast, voltage-dependent sodium current and the L-type calcium currents [38,39] that would allow the arrhythmia to be sustained.

Our study is not without limitations. Data were not available on fish preparation technique. Analysis in the Cardiovascular Health Study have shown that fish preparation method differentially effects the association between fish-derived n-3 PUFAs and CHD, with only intake of tuna and other baked or broiled fish associated with cardiovascular benefits, with no or deleterious associations for fried fish or fish sandwiches [2,40]. Lack of information on fish preparation method in ARIC could be responsible for our failure to show an association between fish intake and AF risk. The relatively low correlation between dietary and plasma EPA and DHA in the ARIC sample further suggests that measurement error is an important limitation.[23] Additionally, the range of fish
intake in our study sample was low. Such a limited range may have inhibited our ability to find an association. Also, diet was measured at baseline and at a follow-up visit, but changes in fish consumption after visit 3 could not be assessed, potentially creating additional nondifferential measurement error of the exposure. Finally, AF ascertainment was mostly based on hospital discharge codes, which limited the ability to identify paroxysmal AF and AF managed in outpatient settings. Our previous validation study, however, suggests that hospital discharges are an adequate method for AF ascertainment in epidemiologic studies [20].

In summary, our results suggest that, in a sample with low-moderate average fish intake, usual fish and n-3 PUFAs intake is not strongly associated with AF risk. We have observed, consistent

### Table 3. Hazard ratios (95% confidence interval) of atrial fibrillation by categories of DHA+EPA intake, ARIC, 1987–2008.

| Dietary DHA+EPA (Quartiles) | Q1       | Q2       | Q3       | Q4       | P for trend |
|-----------------------------|----------|----------|----------|----------|-------------|
| AF cases                    | 402      | 427      | 409      | 366      |             |
| Person-years                | 61,943   | 62,339   | 62,270   | 63,223   |             |
| Model 1 [HR (95% CI)]       | 1 (ref.) | 1.03 (0.90, 1.19) | 1.06 (0.91, 1.23) | 0.95 (0.82, 1.10) | 0.42         |
| Model 2 [HR (95% CI)]       | 1 (ref.) | 1.04 (0.90, 1.20) | 1.06 (0.91, 1.23) | 0.92 (0.79, 1.07) | 0.21         |

| Dietary DHA (Quartiles)     | Q1       | Q2       | Q3       | Q4       |
|-----------------------------|----------|----------|----------|----------|
| AF cases                    | 404      | 428      | 410      | 362      |
| Person-years                | 61,750   | 62,584   | 62,134   | 63,307   |
| Model 1 [HR (95% CI)]       | 1 (ref.) | 1.06 (0.92, 1.22) | 1.05 (0.90, 1.22) | 0.97 (0.83, 1.12) | 0.48         |
| Model 2 [HR (95% CI)]       | 1 (ref.) | 1.06 (0.92, 1.23) | 1.05 (0.90, 1.22) | 0.93 (0.80, 1.09) | 0.21         |

| Dietary EPA (Quartiles)     | Q1       | Q2       | Q3       | Q4       |
|-----------------------------|----------|----------|----------|----------|
| AF cases                    | 412      | 418      | 392      | 382      |
| Person-years                | 61,962   | 62,298   | 62,701   | 62,815   |
| Model 1 [HR (95% CI)]       | 1 (ref.) | 1.07 (0.93, 1.23) | 1.00 (0.86, 1.16) | 0.96 (0.83, 1.12) | 0.41         |
| Model 2 [HR (95% CI)]       | 1 (ref.) | 1.05 (0.91, 1.22) | 1.00 (0.86, 1.16) | 0.93 (0.80, 1.08) | 0.22         |

Dietary DHA and EPA adjusted for energy using the residual method. CI: Confidence interval. HR: Hazard ratio. Model 1: adjusted for age, sex, and race; Model 2: adjusted for center, age, race, sex, energy intake, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.

### Table 4. Hazard ratios (95% confidence interval) of atrial fibrillation by quartiles of Phospholipid DHA and EPA, ARIC Minnesota field center, 1987–2008.

| Phospholipid DHA+EPA (Quartiles) | Q1       | Q2       | Q3       | Q4       | P for trend |
|-----------------------------------|----------|----------|----------|----------|-------------|
| AF cases                          | 112      | 95       | 93       | 101      |             |
| Person-years                      | 16,114   | 16,994   | 16,829   | 17,144   |             |
| Model 1 [HR (95% CI)]             | 1 (ref.) | 0.77 (0.58, 1.01) | 0.80 (0.61, 1.05) | 0.79 (0.60, 1.03) | 0.18         |
| Model 2 [HR (95% CI)]             | 1 (ref.) | 0.80 (0.6, 1.06) | 0.81 (0.61, 1.08) | 0.87 (0.66, 1.15) | 0.54         |

| Phospholipid DHA From Plasma (Quartiles) | Q1       | Q2       | Q3       | Q4       |
|-----------------------------------------|----------|----------|----------|----------|
| AF cases                                | 117      | 86       | 99       | 99       |
| Person-years                            | 16,118   | 16,961   | 16,849   | 17,153   |
| Model 1 [HR (95% CI)]                   | 1 (ref.) | 0.68 (0.52, 0.90) | 0.78 (0.60, 1.02) | 0.74 (0.57, 0.97) | 0.10         |
| Model 2 [HR (95% CI)]                   | 1 (ref.) | 0.71 (0.54, 0.95) | 0.82 (0.62, 1.08) | 0.84 (0.63, 1.11) | 0.47         |

| Phospholipid EPA (Quartiles)            | Q1       | Q2       | Q3       | Q4       |
|-----------------------------------------|----------|----------|----------|----------|
| AF cases                                | 99       | 86       | 106      | 110      |
| Person-years                            | 17,325   | 15,505   | 17,217   | 17,034   |
| Model 1 [HR (95% CI)]                   | 1 (ref.) | 1.00 (0.75, 1.34) | 1.11 (0.84, 1.46) | 1.11 (0.85, 1.46) | 0.38         |
| Model 2 [HR (95% CI)]                   | 1 (ref.) | 0.98 (0.73, 1.31) | 1.04 (0.78, 1.37) | 1.12 (0.85, 1.49) | 0.33         |

CI: Confidence interval. HR: Hazard ratio. Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, BMI, education, exercise levels, smoking status and amount, alcohol intake, HDL-C, LDL-C, use of cholesterol lowering medications, systolic blood pressure, use of antihypertensive medications, diabetes, coronary heart disease, and ECG-defined left ventricular hypertrophy.

doi:10.1371/journal.pone.0036686.t003

doi:10.1371/journal.pone.0036686.t004
with other studies [14], that phospholipid DHA and EPA might have dissimilar associations with the risk of AF.

Acknowledgments

The authors thank the staff and participants of the ARIC study for their important contributions.

References

1. He K, Song Y, Vasquez ML, Liu K, Van Horn L, et al. (2004) Accumulated evidence on fish and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109: 2705–2711.
2. Mozaffarian D, Lemaire RN, Kuller LH, Burke GL, Tracy RP, et al. (2003) Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 107: 1372–1377.
3. Mozaffarian D (2008) Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Clin Nutr 87: 1991S–1996S.
4. Mozaffarian D, Stein PK, Prineas RJ, Siscovick DS (2008) Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation 117: 1130–1137.
5. Leaf A, Kang JX, Xiao YF, Billman GE (2003) Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107: 2656–2652.
6. Breslow JL (2006) N-3 fatty acids and cardiovascular disease. Am J Clin Nutr 83: 261–266.
7. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 125: e18–e209.
8. Berry JD, Prineas RJ, van Horn L, Passman R, Larson J, et al. (2010) Dietary fish intake and incident atrial fibrillation (from the Women’s Health Initiative). Am J Cardiol 105: 844–848.
9. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Wittenman JCM (2006) Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 151: 857–862.
10. Frost L, Yestergaard P (2005) n-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 81: 59–64.
11. Groszynska NN, Alonso A (2010) Diet and risk of atrial fibrillation - epidemiologic and clinical evidence. Circ J 74: 2009–2030.
12. Mozaffarian D, Patsy BM, Rimm EB, Lemaire RN, Burke GL, et al. (2004) Fish intake and risk of incident atrial fibrillation. Circulation 110: 368–373.
13. Shen J, Johnson VN, Sullivan LM, Jacques PF, Magnani JW, et al. (2011) Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr 93: 261–266.
14. Virtanen JK, Mursu J, Vuolteenaho S, Tuomainen T-P (2009) Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 120: 2315–2321.
15. Viviana Anselmi C, Ferreri C, Novelli V, Roncarati R, Brunozzi R, et al. (2010) Fatty acid percentage in erythrocyte membranes of atrial flutter/fibrillation patients and controls. J Interv Card Electrophysiol 27: 95–99.
16. Wu JH, Lemaire RN, King IB, Song X, Sacks FM, et al. (2012) Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the Cardiovascular Health Study. Circulation 125: 1084–1093.
17. Willett WC (2008) Nutritional epidemiology. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins. pp 580–597.
18. The ARIC Investigators (1989) The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 129: 687–702.
19. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, et al. (2010) Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 159: 650–656.
20. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, et al. (2009) Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 158: 111–117.
21. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, et al. (1985) Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 122: 51–65.
22. Riboli E, Roncoli M, Saracci R (1987) Biological markers of diet. Cancer Surv 6: 615–718.
23. Ma J, Folsom AR, Shahar E, Eckfeldt JH (1995) Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin Nutr 62: 564–571.
24. Caule PN, Devereux RB, Alonso D, Campo E, Kligfield P (1987) Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 75: 565–572.
25. Willett WC, Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 124: 17–27.
26. Freedman LS, Tasevska N, Kipsis V, Schatzkin A, Mares J, et al. (2010) Gains in statistical power from using a dietary biomarker in combination with self-reported intake to strengthen the analysis of a diet-disease association: an example from CAREDS. Am J Epidemiol 172: 836–842.
27. Mozaffarian D, Rimm EB (2006) Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296: 1885–1899.
28. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, et al. (2005) N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45: 1723–1728.
29. Mariscalco G, Sarzi Braga S, Banach M, Borsani P, Bruno VD, et al. (2010) Preoperative n-3 polyunsaturated fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 61: 643–650.
30. Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, et al. (2009) Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J 9: 292–296.
31. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, et al. (2010) Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 12: 356–363.

32. Saravanan P, Bridgewater B, West AL, O’Neill SC, Calder PC, et al. (2010) Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Cure Arrhythm Electrophysiol 3: 46–53.

33. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM (2010) Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 304: 2363–2372.

34. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, et al. (2011) n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation 124: 1100–1106.

35. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Leebe LR, et al. (2011) Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 123: 1501–1508.

36. Boos CJ, Anderson RA, Lip GY (2006) Is atrial fibrillation an inflammatory disorder? Eur Heart J 27: 136–149.

37. Mayyas F, Sakurai S, Ram R, Renison JH, Hwang ES, et al. (2011) Dietary omega 3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc Res 89: 852–861.

38. Kang JX, Leaf A (1996) Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur J Pharmacol 297: 97–106.

39. Xiao Y-F, Gomez AM, Morgan JP, Lederer WJ, Leaf A (1997) Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 94: 4182–4187.

40. Mozaffarian D, Gottdiener JS, Siscovick DS (2006) Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics. Am J Cardiol 97: 216–222.